



Multiple Sclerosis Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:	Dosage Form:	
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the medication being requested:					
<input type="checkbox"/> Ampyra	<input type="checkbox"/> Briumvi	<input type="checkbox"/> Gilenya	<input type="checkbox"/> Mavenclad	<input type="checkbox"/> Rebif	
<input type="checkbox"/> Aubagio	<input type="checkbox"/> Copaxone	<input type="checkbox"/> Glatiramer	<input type="checkbox"/> Mayzent	<input type="checkbox"/> Tascenso ODT	
<input type="checkbox"/> Avonex	<input type="checkbox"/> Dalfampridine ER	<input type="checkbox"/> Glatopa	<input type="checkbox"/> Plegridy	<input type="checkbox"/> Tecfidera	
<input type="checkbox"/> Bafiertam	<input type="checkbox"/> Extavia	<input type="checkbox"/> Kesimpta	<input type="checkbox"/> Ponvory	<input type="checkbox"/> Vumerity	
<input type="checkbox"/> Betaseron				<input type="checkbox"/> Zeposia	
Select the diagnosis below:					
<input type="checkbox"/> Multiple sclerosis _____					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Prescriber's specialty:					
Select if the requested medication is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Neurologist					
<input type="checkbox"/> Psychiatrist [Ampyra (dalfampridine ER) only]					
For Ampyra (dalfampridine ER), also answer the following:					
Does the patient have a history of seizures? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For Aubagio, Avonex, Bafiertam, Betaseron, Briumvi, Copaxone, Extavia, Gilenya, Glatiramer, Glatopa, Kesimpta, Lemtrada, Mayzent, Plegridy, Ponvory, Rebif, Tecfidera, or Vumerity, also answer the following:					
Does the patient have a relapsing form of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For mitoxantrone, also answer the following:					
Select the form of multiple sclerosis that applies to the patient:					
<input type="checkbox"/> Progressive relapsing multiple sclerosis					
<input type="checkbox"/> Secondary progressive multiple sclerosis					
<input type="checkbox"/> Worsening relapsing-remitting multiple sclerosis					



Multiple Sclerosis Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

For Mavenclad, also answer the following:

Does the patient have a relapsing form of multiple sclerosis, including relapsing-remitting disease or active secondary progressive disease? ☐ **Yes** ☐ **No**

Has the patient already received the FDA-recommended lifetime limit of 2 treatment courses (or 4 treatment cycles total) of cladribine? ☐ **Yes** ☐ **No**

Select the disease-modifying therapies for multiple sclerosis the patient has failed after a trial of at least 4 weeks, has a contraindication to, or intolerance to:

- | | | |
|--|---|---|
| <input type="checkbox"/> Aubagio (teriflunomide) | <input type="checkbox"/> Extavia (interferon beta-1b) | <input type="checkbox"/> Plegridy (peginterferon beta-1a) |
| <input type="checkbox"/> Avonex (interferon beta-1a) | <input type="checkbox"/> Gilenya (fingolimod) | <input type="checkbox"/> Rebif (interferon beta-1a) |
| <input type="checkbox"/> Bafiertam (monomethyl fumarate) | <input type="checkbox"/> Kesimpta (ofatumumab) | <input type="checkbox"/> Tecfidera (dimethyl fumarate) |
| <input type="checkbox"/> Betaseron (interferon beta-1b) | <input type="checkbox"/> Lemtrada (alemtuzumab) | <input type="checkbox"/> Tysabri (natalizumab) |
| <input type="checkbox"/> Briumvi (ublituximab-xiiy) | <input type="checkbox"/> Mayzent (siponimod) | <input type="checkbox"/> Vumerity (diroximel) |
| <input type="checkbox"/> Copaxone/Glatopa (glatiramer acetate) | <input type="checkbox"/> Ocrevus (ocrelizumab) | <input type="checkbox"/> Zeposia (ozanimod) |

Quantity limit requests:

What is the quantity requested per MONTH? _____

What is the reason for exceeding the plan limitations?

- ☐ Titration or loading dose purposes
- ☐ Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- ☐ Requested strength/dose is not commercially available
- ☐ Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call 1-855-401-4262.
This form may be used for non-urgent requests and faxed to 1-844-403-1029.